23 Jul, 2026
The global sleep apnea devices market size, valued at USD 7.66 billion in 2025, is forecast to climb from USD 8.18 billion in 2026 to USD 13.99 billion by 2034, reflecting a CAGR of 6.94% throughout the forecast period (2026–2034).
The abnormal breathing pattern that a person experiences while they are asleep is a sign of the sleeping disorder known as sleep apnea. People with untreated sleep apnea experience interrupted breathing while they sleep because untreated sleep apnea results in the brain and the rest of the body receiving insufficient oxygen. This condition is more prevalent in older patients and those with diabetes, hypertension, cardiovascular disorders, and others. The most pervasive form of obstructive sleep apnea (OSA) must be diagnosed early and treated with devices.
Comorbidities associated with sleep apnea include obesity, diabetes, cardiovascular disease, and hypertension. It has been discovered that 73% of patients with episodes of stable heart failure have sleep breathing problems, which are frequently characterized by apnea and hypopnea. Sleep apnea is also one of the leading causes of hypertension. The severity of SDB is inversely correlated with the likelihood of developing hypertension. More people are likely to seek out sleep apnea diagnosis and treatment in light of the prevalence of these comorbidities, driving up the demand for sleep apnea devices.
People choose home sleep apnea tests (HSATs) more frequently because of their accessibility and simplicity of sleep apnea management at home. The pandemic has also increased the demand for telemedicine, which is anticipated to boost the market growth. The market for sleep apnea devices is growing due to emerging advanced technologies like artificial intelligence (AI).
North America is the most significant shareholder in the global sleep apnea market and is expected to grow at a CAGR of 5.70% during the forecast period. North America is one of the leading regions for adopting sleep disorder-related technology. Some sleeping disorders are driving the market as respiratory diseases become more common. The presence of foreign manufacturers, the sizeable patient base, and the rising prevalence of sleep apnea are additional factors expected to boost this region's market share. The growing use of sleep apnea devices by people who have sleep disorders or other medical conditions that can cause them is another factor driving growth.
Europe is anticipated to grow at a CAGR of 6.2%, generating USD 1,803.61 million during the forecast period. The top five European countries with the highest prevalence of sleep apnea are Russia, Germany, France, Ukraine, Spain, and the United Kingdom (8 million). In Europe, there are three times as many people with sleep apnea as in the US. However, fewer people are diagnosed in this region than in North America due to a lack of knowledge about sleep disorders. The market will likely be driven by the rising incidence of sedentary lifestyle-related diseases like obesity over the forecast period.
The increasing geriatric population and the rising prevalence of lifestyle diseases are two significant factors driving the Asia Pacific sleep apnea devices market. The major players in the market are launching innovative products and other tactical initiatives to expand their market share and increase public awareness of the market's primary driver, sleep apnea. The area's failing healthcare infrastructure will likely aid growth. A further factor driving the market during the forecast period is the establishment of sleep laboratory facilities for testing patients with sleep apnea in countries like the Philippines, Singapore, and Malaysia.
sales@straitsresearch.com